13F Holdings
中文EN

ORKA Oruka Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 907654 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-18.1%
ROA-17.5%
ROIC (approx.)-20.6%
Asset turnover—

Leverage & solvency

Liabilities / assets2.8%
Debt / equity0.00x
Current ratio29.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-3.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31FY20202020-12-31
Income statement
Revenue—$0$0$0$0
R&D expense$100.64M$1.01M$4.75M$13.83M$4.99M
SG&A expense$21.41M$6.28M$5.85M$5.50M$4.77M
Operating income-$122.05M-$7.30M-$10.60M-$19.34M-$9.77M
Interest expense————$9,000
Pretax income-$105.43M——-$19.32M-$9.75M
Income tax—$0$0$0-$9,000
Net income-$105.43M-$5.34M-$9.93M-$19.32M-$9.74M
EBITDA-$121.97M-$7.28M-$10.58M-$19.32M-$9.76M
EPS (basic)—-0.37-0.69-1.39-2.07
EPS (diluted)—-0.37-0.69-1.39-2.07
Weighted avg. shares (diluted)—14.42M14.41M13.90M4.71M
Balance sheet
Cash & equivalents$46.94M$37.43M$42.45M$53.36M$49.07M
Short-term investments$290.11M————
Current assets$343.86M$37.59M$42.70M$54.42M$49.97M
PP&E, net$288,000$10,000$25,000$48,000$21,000
Total assets$488.62M$37.86M$43.09M$54.92M$50.43M
Current liabilities$15.37M$637,000$1.13M$3.50M$3.50M
Total liabilities$16.69M$841,000$1.41M$3.88M$3.91M
Shareholders' equity$471.93M$37.02M$41.67M$51.04M$46.52M
Shares outstanding48.72M14.50M14.41M14.41M9.55M
Cash flow statement
Operating cash flow-$88.21M-$5.01M-$10.91M-$18.76M-$7.72M
Capital expenditure$209,000$0$2,000$43,000$19,000
Free cash flow-$88.42M-$5.01M-$10.91M-$18.80M-$7.74M
Investing cash flow-$96.75M$0-$2,000-$43,000-$19,000
Financing cash flow$170.31M$0$0$23.09M$48.45M
Depreciation & amortization$83,000$15,000$20,000$16,000$8,000
Stock-based compensation$24.24M$686,000$556,000$497,000$43,000

Free plan shows the latest 5 periods; Pro shows all 21 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.